Prognostic factors in chemotherapy-treated patients with HIV-associated plasmablastic lymphoma

Oncologist

Volumn 15, Issue 3, 2010, Pages 293-299

  Castillo, Jorge J ^a   Winer, Eric S ^a   Stachurski, Dariusz ^a   Perez, Kimberly ^a   Jabbour, Melhem ^b   Milani, Cannon ^b   Colvin, Gerald ^a   Butera, James N ^a  

^a BROWN UNIVERSITY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; HIV; PBL; Plasmablastic lymphoma; Prognostic factors

Indexed keywords

CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VINCRISTINE; VIRUS RNA; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ADVANCED CANCER; ANTIGEN EXPRESSION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CD4 LYMPHOCYTE COUNT; CHILD; CONTROLLED STUDY; DRUG EFFICACY; EARLY CANCER; EPSTEIN BARR VIRUS; FEMALE; HIV ASSOCIATED PLASMABLASTIC LYMPHOMA; HIV ASSOCIATED PLASMABLASTIC LYMPHOMAA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; COMPLICATION; LYMPHOMA, AIDS-RELATED; LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC; MIDDLE AGED; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HIV INFECTIONS; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 77950535702     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0304     Document Type: Article

References (29)

1. Delecluse HJ, Anagnostopoulos I, Dallenbach F et al. Plasmablastic lymphomas of the oral cavity: A new entity associated with the human immu-nodeficiency virus infection. Blood 1997;89:1413-1420.
2. Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: Lessons learned from 112 published cases. Am J Hematol 2008; 83:804-809.
3. Armstrong R, Bradrick J, Liu YC. Spontaneous regression of an HIV-associated plasmablastic lymphoma in the oral cavity: A case report. J Oral Maxillofac Surg 2007;65:1361-1364.
4. Gilaberte M, Gallardo F, Bellosillo B et al. Recurrent and self-healing cutaneous monoclonal plasmablastic infiltrates in a patient with AIDS and Kaposi sarcoma. Br J Dermatol 2005;153:828-832.
5. Nasta SD, Carrum GM, Shahab I et al. Regression of a plasmablastic lymphoma in a patient with HIV on highly active antiretroviral therapy. Leuk Lymphoma 2002;43:423-426.
6. Brown RS, Power DA, Spittle HF et al. Absence of immunohistochemical evidence for human herpesvirus 8 (HHV8) in oral cavity plasmablastic lymphoma in an HIV-positive man. Clin Oncol (R Coll Radiol) 2000;12: 194.
7. Gaidano G, Cerri M, Capello D et al. Molecular histogenesis of plasmablastic lymphoma of the oral cavity. Br J Haematol 2002;119:622-628.
8. Lester R, Li C, Phillips P et al. Improved outcome of human immunodeficiency virus-associated plasmablastic lymphoma of the oral cavity in the era of highly active antiretroviral therapy: A report of two cases. Leuk Lymphoma 2004;45:1881-1885.
9. Ojanguren J, Collazos J, Martinez C et al. Epstein-Barr virus-related plasmablastic lymphomas arising from long-standing sacrococcygeal cysts in immunosuppressed patients. AIDS 2003;17:1582-1584.
10. Panos G, Karveli EA, Nikolatou O et al. Prolonged survival of an HIV-infected patient with plasmablastic lymphoma of the oral cavity. Am J He-matol 2007;82:761-765.
11. Mounier N, Spina M, Gabarre J et al. AIDS-related non-Hodgkin lymphoma: Final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood 2006;107:3832-3840.
12. Bohlius J, Schmidlin K, Costagliola D et al.; Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. AIDS 2009;23:2029-2037.
13. Swerdlow S, Campo E, Harris N et al. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues, Fourth Edition. Lyon, France: IARC, 2008:256-257.
14. Adam P, Katzenberger T, Seeberger H et al. A case of a diffuse large B-cell lymphoma of plasmablastic type associated with the t(2;5)(p23;q35) chromosome translocation. Am J Surg Pathol 2003;27:1473-1476.
15. Rafaniello Raviele P, Pruneri G, Maiorano E. Plasmablastic lymphoma: A review. Oral Dis 2009;15:38-45.
16. Bower M, Gazzard B, Mandalia S et al. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med 2005;143:265-273.
17. Miralles P, Berenguer J, Ribera JM et al. Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors. J Acquir Immune Defic Syndr 2007;44:167-173.
18. Chang CC, Zhou X, Taylor JJ et al. Genomic profiling of plasmablastic lymphoma using array comparative genomic hybridization (aCGH): Revealing significant overlapping genomic lesions with diffuse large B-cell lymphoma. J Hematol Oncol 2009;2:47.
19. Savage KJ, Johnson NA, Ben-Neriah S et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009;114:3533-3537.
20. Bogusz AM, Seegmiller AC, Garcia R et al. Plasmablastic lymphomas with MYC/IgH rearrangement: Report of three cases and review of the literature. Am J Clin Pathol 2009;132:597-605.
21. Bose P, Thompson C, Gandhi D et al. AIDS-related plasmablastic lymphoma with dramatic, early response to bortezomib. Eur J Haematol 2009; 82:490-492.
22. Dawson MA, Schwarer AP, McLean C et al. AIDS-related plasmablastic lymphoma of the oral cavity associated with an IGH/MYC translocation-treatment with autologous stem-cell transplantation in a patient with severe haemophilia-A. Haematologica 2007;92:e11-e12.
23. Yotsumoto M, Ichikawa N, Ueno M et al. CD20-negative CD138-positive leukemic large cell lymphoma with plasmablastic differentiation with an IgH/MYC translocation in an HIV-positive patient. Intern Med 2009;48: 559-562.
24. Dunleavy K, Pittaluga S, Czuczman MS et al. Differential efficacy of bort-ezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009;113:6069-6076.
25. ClinicalTrials.gov. Bortezomib, ifosfamide, carboplatin, and etoposide, with or without rituximab, in treating patients with relapsed or refractory AIDS-relatednon-Hodgkinlymphoma. Available at http://www.clinicaltrials.gov, accessed February 11, 2010.
26. ClinicalTrials.gov. Study to assess the effectiveness of RCHOP with or without VELCADE in previously untreated non-germinal center B-cell-like diffuse large B-cell lymphoma patients. Available at http://www.clinicaltrials.gov, accessed February 11, 2010.
27. Flaitz CM, Nichols CM, Walling DM et al. Plasmablastic lymphoma: An HIV-associated entity with primary oral manifestations. Oral Oncol 2002; 38:96-102.
28. Kaplan LD, Lee JY, Ambinder RF et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without ritux-imab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 2005;106:1538-1543.
29. Boué F, Gabarre J, Gisselbrecht C et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol 2006;24:4123-4128.